Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

diamedica therapeutics inc - DMAC

DMAC

Close Chg Chg %
6.22 0.11 1.77%

Closed Market

6.33

+0.11 (1.77%)

Volume: 130.99K

Last Updated:

Apr 24, 2026, 4:00 PM EDT

Trade Now

Company Overview: diamedica therapeutics inc - DMAC

DMAC Key Data

Open

$6.20

 Day Range

6.00 - 6.35

52 Week Range

3.48 - 10.42

 Market Cap

$345.93M

Shares Outstanding

53.88M

 Public Float

26.97M

Beta

1.15

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.70

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

196.21K

  

DMAC Performance

1 Week
 
 -7.59%
 
1 Month
 
 -6.77%
 
3 Months
 
 -25.62%
 
1 Year
 
 56.68%
 
5 Years
 
 -35.01%
 

DMAC Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About diamedica therapeutics inc - DMAC

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.

DMAC At a Glance

DiaMedica Therapeutics, Inc.
301 Carlson Parkway
Minneapolis, Minnesota 55305
Phone 1-763-496-5454 Revenue 0.00
Industry Biotechnology Net Income -32,766,000.00
Sector Health Technology Employees 35
Fiscal Year-end 12 / 2026
View SEC Filings

DMAC Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 7.624
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -9.149
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.001

DMAC Efficiency

Revenue/Employee N/A
Income Per Employee -936,171.429
Receivables Turnover N/A
Total Asset Turnover N/A

DMAC Liquidity

Current Ratio 11.814
Quick Ratio 11.814
Cash Ratio 11.67

DMAC Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -60.838
Return on Equity -67.678
Return on Total Capital -58.146
Return on Invested Capital -67.424

DMAC Capital Structure

Total Debt to Total Equity 0.428
Total Debt to Total Capital 0.426
Total Debt to Total Assets 0.391
Long-Term Debt to Equity 0.228
Long-Term Debt to Total Capital 0.227
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Diamedica Therapeutics Inc - DMAC

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
25.00K 30.00K 39.00K 43.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
25.00K 30.00K 39.00K 43.00K
Depreciation
25.00K 30.00K 39.00K 43.00K
Amortization of Intangibles
- - - -
-
COGS Growth
+4.17% +20.00% +30.00% +10.26%
Gross Income
(25.00K) (30.00K) (39.00K) (43.00K)
Gross Income Growth
-4.17% -20.00% -30.00% -10.26%
Gross Profit Margin
- - - -
-
2022 2023 2024 2025 5-year trend
SG&A Expense
13.98M 21.24M 26.64M 34.35M
Research & Development
7.84M 13.11M 19.06M 24.61M
Other SG&A
6.14M 8.13M 7.59M 9.74M
SGA Growth
+2.60% +51.95% +25.45% +28.95%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(14.00M) (21.27M) (26.68M) (34.40M)
Non Operating Income/Expense
353.00K 1.93M 2.27M 1.66M
Non-Operating Interest Income
- - 2.30M 1.67M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(13.65M) (19.34M) (24.41M) (32.74M)
Pretax Income Growth
-0.62% -41.69% -26.25% -34.10%
Pretax Margin
- - - -
-
Income Tax
28.00K 43.00K 30.00K 28.00K
Income Tax - Current - Domestic
- - 28.00K 24.00K
-
Income Tax - Current - Foreign
- - - 4.00K
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(13.68M) (19.38M) (24.44M) (32.77M)
Minority Interest Expense
- - - -
-
Net Income
(13.68M) (19.38M) (24.44M) (32.77M)
Net Income Growth
-0.62% -41.72% -26.12% -34.05%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(13.68M) (19.38M) (24.44M) (32.77M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(13.68M) (19.38M) (24.44M) (32.77M)
EPS (Basic)
-0.5172 -0.5951 -0.605 -0.6974
EPS (Basic) Growth
+20.95% -15.06% -1.66% -15.27%
Basic Shares Outstanding
26.44M 32.57M 40.40M 46.98M
EPS (Diluted)
-0.5172 -0.5951 -0.605 -0.6974
EPS (Diluted) Growth
+20.95% -15.06% -1.66% -15.27%
Diluted Shares Outstanding
26.44M 32.57M 40.40M 46.98M
EBITDA
(13.98M) (21.24M) (26.64M) (34.35M)
EBITDA Growth
-2.60% -51.95% -25.45% -28.95%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 12.333
Number of Ratings 5 Current Quarters Estimate -0.191
FY Report Date 06 / 2026 Current Year's Estimate -0.761
Last Quarter’s Earnings -0.185 Median PE on CY Estimate N/A
Year Ago Earnings -0.70 Next Fiscal Year Estimate -0.836
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 4 5 5
Mean Estimate -0.19 -0.21 -0.76 -0.84
High Estimates -0.17 -0.17 -0.60 -0.62
Low Estimate -0.21 -0.24 -0.92 -1.05
Coefficient of Variance -9.81 -15.25 -16.58 -21.77

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 5 5
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Diamedica Therapeutics Inc - DMAC

Date Name Shares Transaction Value
Apr 21, 2026 James T. Parsons 73,604 Grant of rights 0.00
Apr 21, 2026 Charles P. Semba 35,176 Grant of rights 0.00
Apr 21, 2026 Charles P. Semba 31,821 Grant of rights 0.00
Apr 21, 2026 Charles P. Semba 26,531 Grant of rights 0.00
Apr 21, 2026 Charles P. Semba 17,156 Grant of rights 0.00
Apr 21, 2026 Charles P. Semba N/A Opening Balance – Initial SEDI Report 0.00
Apr 21, 2026 Rick John Pauls 49,189 Grant of rights 0.00
Apr 21, 2026 Rick John Pauls 39,094 Grant of rights 0.00
Apr 21, 2026 Rick John Pauls 23,177 Grant of rights 0.00
Apr 21, 2026 Rick John Pauls 4,729,500 Grant of options 0.00
Apr 21, 2026 Rick John Pauls 4,353,500 Grant of options 0.00
Apr 21, 2026 Rick John Pauls 54,055 Acquisition or disposition under a prospectus exemption Non-derivative transaction at $1.21 per share 65,406.55
Apr 21, 2026 Michael R. Giuffre 463,250 Grant of options 0.00
Apr 21, 2026 Michael R. Giuffre 105,337 Grant of rights 0.00
Apr 21, 2026 Michael R. Giuffre 99,162 Grant of rights 0.00
Apr 21, 2026 Michael R. Giuffre 88,301 Grant of rights 0.00
Apr 21, 2026 Michael R. Giuffre 69,105 Grant of rights 0.00
Apr 21, 2026 James T. Parsons 142,127 Grant of options 0.00
Apr 21, 2026 James T. Parsons 83,699 Grant of rights 0.00
Apr 21, 2026 James T. Parsons 57,687 Grant of rights 0.00

Diamedica Therapeutics Inc in the News